SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction

SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction

SciSparc Ltd. SPRC collaboration with Clearmind Medicine Inc. CMNDF CMND CWY resulted in the filing of a provisional patent application related to treating cocaine addiction.

The patent application refers to the proprietary combination of SciSparc's CannAmide with Clearmind's MEAI, for treating cocaine addiction.

In the United States cocaine addiction peaked in the 1990s, and the current estimates by the National Institute on Drug Abuse claim at least 1.3 million Americans are addicted to cocaine. Annually, these users go to the hospital more than 350,000 times and account for 54% of drug-related incarcerations in federal jails and prisons, according to recent statistics from the U. S. Department of Justice. In addition, cocaine is either suspected or confirmed as the cause for nearly 16,000 overdose deaths each year in the United States. Furthermore, it is at least a contributing factor in many more deaths, usually from violence, associated medical conditions or other health impacts of the user’s lifestyle.

"The continuous successes of our relatively new collaboration with Clearmind strengthen our belief that combining our CannAmide with Clearmind's novel psychedelic molecule, MEAI, holds great potential for treating various addictions and dependency conditions,” stated Oz Adler, SciSparc's CEO. “Cocaine abuse in the United States is a serious and growing issue that affects all ages. Despitethe highly addictive nature of cocaine, a dedicated treatment for this addiction does not currently exist,which makes the potential for our treatment even more exciting. In light of the encouraging results generated from this collaboration and following our first patent application for binge behavior announced in May, we intend to continue to strengthen and expand our collaboration with Clearmind."

Photo by Julia Koblitz on Unsplash

Related News

SciSparc Announces $10M Private Offering

Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results

Posted In: Oz AdlerCannabisNewsPenny StocksPsychedelicsMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.